An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at
AUSTIN, Texas , March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD
$121.1 Million In Cash and Cash Equivalents at December 31, 2023 , With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants. A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies. Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.
Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW” Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas , Jan.
Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of Charge Warrants Are Expected to List and Trade on Nasdaq Warrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government AUSTIN, Texas , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease,
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024. Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025.
Safety Finding Based on Blinded MRI Brain Data at Week 40 ARIA is a Known Risk Factor for Anti-Amyloid Antibody Drugs MRI Data Presented at the 16 th CTAD Conference in Boston, MA AUSTIN, Texas , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
